| Rational targeting in acute promyelocytic leukemia. | |
| | |
MedLine Citation:
|
PMID: 20133971 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Acute promyelocytic leukemia (ARL) is characterized by the nearly homogeneous expression of the fusion oncogenic protein PML-RARalpha and the testis-specific cyclin A1 protein, which are implicated in its pathogenesis. PML-RARalpha binds all-trans retinoic acid with high affinity inducing granulocytic differentiation and remission. Current approaches with high doses of single or combined all-trans retinoic acid and chemotherapeutic agents, though relatively efficacious in the beginning, are highly toxic with severe side-effects (retinoic acid syndrome) and are followed by relapse in a high proportion of patients. Here it is proposed that targeting APL with low levels of all-trans retinoic acid combined with small molecule inhibitors of cyclin-dependent kinases may have the potential to be equally or more efficacious as any of the current single or combined agent approaches, affording reduced toxicity and relapse rates. |
| | |
Authors:
|
Nikolaos A Papanikolaou |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: In vivo (Athens, Greece) Volume: 24 ISSN: 0258-851X ISO Abbreviation: In Vivo Publication Date: 2010 Jan-Feb |
Date Detail:
|
Created Date: 2010-02-05 Completed Date: 2010-04-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8806809 Medline TA: In Vivo Country: Greece |
Other Details:
|
Languages: eng Pagination: 21-7 Citation Subset: IM |
Affiliation:
|
Aristotle University of Thessaloniki, School of Medicine, Laboratory of Biological Chemistry, University Campus PO Box 1686, Thessaloniki 54124, Greece. papanikn@med.auth.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
adverse effects,
therapeutic use* Antineoplastic Combined Chemotherapy Protocols / pharmacology, therapeutic use Cyclin-Dependent Kinases / antagonists & inhibitors Dose-Response Relationship, Drug Drug Delivery Systems* Drug Resistance, Neoplasm / drug effects Enzyme Inhibitors / pharmacology Humans Leukemia, Promyelocytic, Acute / drug therapy* Tretinoin / pharmacology, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Enzyme Inhibitors; 302-79-4/Tretinoin; EC 2.7.11.22/Cyclin-Dependent Kinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Screening of antimicrobial agents for in vitro radiation protection and mitigation capacity, includi...
Next Document: Effect of contact with titanium alloys on the proliferation of mouse osteoblastic cells in culture.